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EDITORIAL
“Most journals avoid publishing reviews and case studies 
unless these offer unique and/or paradigm shifting options 
in enhancing clinical practice” – this was part of my editorial 
comment in March 2020. 
As it happens, I should be more accurate and acknowledge 
that often original research is suboptimal (for many reasons) 
and many submissions are consequently rejected (sadly for 
the researchers). As such a default option is applied (perhaps 
regrettably so) and the “best” case reports (that are somewhat 
more immune to the challenge in study design, methodology, 
sample size, statistical analyses and other basic errors in research 
undertaking), are successful. This is perhaps a realisation that 
academic departments should take heed of the diagnosis and 
offer treatment by re-igniting original research of a higher quality. 
Perhaps this is also a call to the SEMDSA Executive to lead this 
process and perhaps initiate and coordinate more collaboration 
and research in the country/subcontinent.     
The three case reports are nonetheless most instructive – 
devastating neurological fallout occurs with a delay in the 
diagnosis of insulinoma (Dire Z, et al.), lysosomal storage 
diseases are rare, allude to the better understanding of lipid 
pathways and are manageable in the long term (Angamia Z, et 
al.) and rare neuro-endocrine disease may cause even more rare 
“orbitopathy” (Hoenck H, et al.).
“Thus during the ensuing 12 months some 5.1 million additional 
human deaths will be attributed to diabetes, roughly one 
death every seven seconds” – this was also part of my editorial 
comment (a perspective to the current focus on COVID-related 
mortality) in March 2020 and I questioned how we, in South 
Africa, inadvertently contribute to this high number. An instruc-
tive, longitudinal study (Hoosen M, et al.) provides part of this 
answer – their audit tracts improved glyacemia control in 58 
patients with T1 diabetes during a 10-year period of follow-up (a 
well-deserved pat on the back), but the ideal target HbAic of 7% 
or less was achieved and sustained in less than 10% of patients 
with a resultant increase in the incidence of complications (so 
this pat is withdrawn).    
Happy reading, do more studies and fewer case reports and stay 
safe.
Jeff Wing
